|
05.16.10
|
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
|
![]()
|
The prevalence of peripheral neuropathy (PNP) during the treatment of MM with Bortezomib is high.
About 20% of patients develop a grade 3-4 PNP due to this treatment, and as a result Bortezomib treatment is
stopped or a reduced dose is given. Therefore, there is a strong need to find markers which predict the
susceptibility of a patient to develop Bortezomib related PNP.
Click the PDF tab to view and dowload the document |
|
|
|
05.16.10
|
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
|
![]()
|
The proteasome inhibitor bortezomib has demonstrated high antitumor
activity in multiple myeloma (MM). Peripheral neuropathy (PNP) is a doselimiting toxicity of bortezomib, which typically occurs within the first cycles of bortezomib in 30-40% of MM patients. Although bortezomib induced PNP is manageable and reversible in most MM patients, no effective prophylactic treatment against PNP is available and bortezomib discontinuation is frequently required. Identifying patients at risk of neuropathy and understanding its pathogenesis is therefore of great importance.
Click on PDF tab to view and download the document |
|
|
|
|
|
|
05.16.10
|
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
|
![]()
|
It is anticipated that inherited single nucleotide polymorphisms (SNPs) in genes involved in drug absorption, distribution, metabolism and excretion influence individual response to thalidomide therapies in Multiple Myeloma. We extracted peripheral blood DNA from 631 myeloma patients of European descent enrolled in the MRC Myeloma IX trial who had received induction thalidomide (50-200mg). We genotyped 3404 SNPs selected in 983 candidate genes that may influence myeloma disease response, toxicity, and/or survival, on a “Bank on a Cure” (BOAC) Affymetrix® true-tag array.
Click on the PDF tab to view and download the document |
|
|
|
|
|
|
|
|
Four abstracts based on data from Bank On A Cure® have been accepted for presentaion at ASH 2009 in New Orleans. You can see videos made by the investigators and review their presentations by following the links below. There is also a video by Dr. Brian Durie summarizing the current status of Bank On A Cure®. |
|
|
|
12.02.09
|
Bank On A Cure® at ASH 2008
|
![]()
|
Drs. Van Ness and Morgan presented Bank On A Cure® findings relating single nucleotide polymorphisms to long term survival and neuropathy |
|
|
|
12.30.07
|
Bank On A Cure® at ASH 2007
|
![]()
|
Dr. Brian Durie's abstract presentation on results from Bank On A Cure® research relating bone disease to genetic polymorphisms singled out as part of 2007's "Best of ASH" session |
|
|
|
|
|
|
|
|
12.31.06
|
Bank On A Cure® Updates from ASH 2006
|
![]()
|
In a significant ASH session, researchers working with the IMF’s unprecedented global, collaborative Bank On A Cure® initiative presented data identifying genetic pathways that may explain why some patients suffer from blood clots when undergoing thalidomide therapy for myeloma. |
|
|
|
|
|
|
|
Dr. Brian Van Ness was on hand to accept the check. |
|
|
|
|
|
07.15.06
|
Progress Report: Bank On A Cure® Research Initiative
|
![]()
|
The goal of Bank On A Cure is to collect DNA samples from at least 10,000 participants. Processing and analyzing this data will yield important clues about each individual person's response to treatment and susceptibility to toxic side effects. This will help researchers gain a greater understanding of how myeloma drugs work, and how they can be improved. Bank On A Cure data will also provide vital insights into the causes of myeloma, and, ultimately, will lead to its prevention and a cure. |
|
|
print
back to top